125-Iodine-labeled MFE-23

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Name125-Iodine-labeled MFE-23
Drug Alias Name125-I-labeled MFE-23-his (Cancer Research UK)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulators
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCancer Research UK
China Registration ClassN/A

Develop Information

Active CompaniesCancer Research UK
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A